SCHEMBL7002755

SCHEMBL7002755

COCc1c(OC(C)C(C)=O)ccc2c(C)cc(=O)oc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.58
KMT2A Q03164 7/20 0.52
MEN1 O00255 1/20 0.52
HPGD P15428 8/20 0.50
HSD17B10 Q99714 7/20 0.50
GAA P10253 7/20 0.50
GLA P06280 4/20 0.50
MAPK1 P28482 3/20 0.50
LMNA P02545 1/20 0.50
MCL1 Q07820 1/20 0.49
ALDH1A1 P00352 8/20 0.48
TSHR P16473 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
MAPT P10636 5/20 0.46
CASP1 P29466 2/20 0.46
CASP7 P55210 2/20 0.46
TP53 P04637 1/20 0.45
HTT P42858 1/20 0.45
CYP1A2 P05177 1/20 0.45
POLB P06746 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6993185 0.80 KDM4E (0.52) KDM4EKMT2AMEN1HPGDHSD17B10
SCHEMBL7001521 0.76 MAOA (0.63) KDM4EKMT2AHPGDHSD17B10GAA
SCHEMBL14756285 0.71 KDM4E (0.62) KDM4EKMT2AHPGDHSD17B10GAA
SCHEMBL6991771 0.70 KDM4E (0.62) KDM4EKMT2AHPGDHSD17B10GAA
SCHEMBL11066632 0.69 KDM4E (0.61) KDM4EKMT2AHPGDHSD17B10GAA
SCHEMBL14756302 0.69 MCL1 (0.72) KDM4EKMT2AHPGDHSD17B10GAA
SCHEMBL15984892 0.68 KDM4E (0.74) KDM4EKMT2AHPGDHSD17B10GAA
SCHEMBL6904917 0.68 KDM4E (0.67) KDM4EKMT2AMEN1HPGDHSD17B10
SCHEMBL11384270 0.68 SRD5A1 (0.67) KDM4EKMT2AHPGDHSD17B10GAA
SCHEMBL11382092 0.67 KDM4E (0.56) KDM4EKMT2AHPGDHSD17B10GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1032265-B1 NEW PSORALENS FOR PATHOGEN INACTIVATION CERUS CORP (US) 2003-10-29 EP disclosed
US-20030082510-A1 Psoralens for pathogen inactivation CERUS CORPORATION (US) 2003-05-01 US disclosed
US-6455286-B1 MIXING PSORALEN COMPOUND OF DEFINED STRUCTURE WITH BIOLOGICAL COMPOSITION SUCH AS BLOOD OR PLATELETS, THEN PHOTOACTIVATING COMPOUND TO DEACTIVATE PATHOGEN CERUS CORPORATION 2002-09-24 US disclosed
EP-1032265-A4 NEW PSORALENS FOR PATHOGEN INACTIVATION CERUS CORP (US) 2001-05-30 EP disclosed
US-6133460-A HAVE PRIMARY AMINO SUBSTITUTIONS ON THE 3-, 4-, 5-, AND 8-POSITIONS OF THE PSORALEN WHICH PERMIT BINDING TO NUCLEIC ACID OF PATHOGENS; CONDITIONS THAT PHOTOACTIVATE THESE PSORALENS RESULT IN INACTIVATION OF PATHOGENS WHICH CONTAIN NUCLEIC ACID CERUS CORPORATION (US) 2000-10-17 US disclosed
EP-1032265-A1 NEW PSORALENS FOR PATHOGEN INACTIVATION Cerus Corporation (US) 2000-09-06 EP disclosed
WO-1999026476-A1 NEW PSORALENS FOR PATHOGEN INACTIVATION CERUS CORPORATION (US) 1999-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030082510-A1 Psoralens for pathogen inactivation BPGM, XPA, RAD50 KDM4E 3035/4885KMT2A 2413/4885MEN1 3663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.